Measurement of airway inflammation in asthma.
Chronic airway inflammation is considered responsible for symptoms and disorders of airway function associated with asthma. This process is the target of anti-inflammatory therapy, so a number of standardized, noninvasive techniques have been developed to assess it. More recent approaches include the measurement of exhaled gases and nonvolatile substances in breath condensate. Results from studies using a wide variety of inflammatory markers have shown group differences between patients with asthma and healthy control subjects, but evidence for the diagnostic use of these markers in individual patients is scarce. Similarly, despite many studies demonstrating some correlation between markers of airway inflammation and a measure of disease control, none has yet convincingly shown a place for the use of these markers in an individual with corticosteroid-treated asthma. However, application of these markers continues to further our understanding of the disease process and provides the potential for more appropriate, customized therapy.
Wilson
Nicola
N
Department of Paediatrics, Royal Brompton and Harefield National Health Service Trust, London, United Kingdom. n.wilson@rbh.nthames.nhs.uk
D001249:Asthma / Q000175:diagnosis / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy*; D015415:Biomarkers / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis; D001944:Breath Tests; D047091:Eosinophil Granule Proteins; D004804:Eosinophils / Q000502:physiology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology; D009569:Nitric Oxide / Q000502:physiology; D012260:Ribonucleases; D013183:Sputum / Q000166:cytology
D015415:Biomarkers; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D005938:Glucocorticoids; D018836:Inflammation Mediators; D009569:Nitric Oxide; D012260:Ribonucleases